Harrow Has Acquired TYRVAYA Nasal Spray From Viatris

The acquisition expands the Nashville-based company's portfolio of treatments for dry eye disease.

Updated on Oct. 6, 2026 in Healthcare

Isometric editorial illustration of a stylized, matte geometric nasal spray delivery device on a clean surface, representing pharmaceutical acquisition. — Harrow has acquired the worldwide rights to the FDA-approved nasal spray TYRVAYA from Viatris in a deal valued at up to $100 million. AI Illustration. Upload story photo >

Live Poll

Does consolidation of prescription brands by fewer companies generally improve access to affordable medications?

Harrow has closed its acquisition of the FDA-approved nasal spray TYRVAYA from Viatris, securing worldwide rights to the drug outside of Japan. The deal includes an initial cash payment of $30 million, with potential milestone payments of up to $70 million.

Why it matters

Harrow aims to strengthen its competitive position in the U.S. dry eye market by integrating TYRVAYA alongside its existing VEVYE treatment. The acquisition includes the transfer of approximately 40 commercial employees from Viatris to bolster sales efforts.

Harrow paid $30 million at closing and expects the drug to generate over $30 million in revenue in 2027. Additionally, 40 Viatris personnel are transitioning to the company as part of the deal.

The players

Harrow

A pharmaceutical company headquartered in Nashville, Tennessee, that focuses on ophthalmic products.

Viatris

A global healthcare company that develops, manufactures, and markets a wide range of pharmaceutical products.

The details

TYRVAYA is an FDA-approved nasal spray designed to treat dry eye disease and holds regulatory approvals in the U.S., China, and Taiwan. While Harrow gains global rights, Viatris will retain commercial rights in Japan and receive royalties on future net sales there.

August 2026: Harrow announced the acquisition terms.
October 05, 2026: The acquisition of TYRVAYA officially closed.
Fourth quarter 2026: Harrow will onboard 40 new commercial personnel.
2027: The company expects TYRVAYA to contribute more than $30 million in revenue.

Market Landscape

This acquisition reflects a broader consolidation trend within the U.S. dry eye therapeutic market as firms seek to build comprehensive treatment portfolios. By absorbing the TYRVAYA asset, Harrow positions itself to better compete with larger pharmaceutical rivals for market share.

Patients currently using the nasal spray will see no immediate disruption to their care, as prescriptions can be sent to PhilRx or any retail pharmacy. The expansion of the commercial team suggests that accessibility to the drug may increase for those seeking dry eye relief.

The takeaway

Companies often prioritize acquiring established assets like TYRVAYA to quickly scale their market presence without the wait time of internal drug development. Investors and patients should monitor how the integration of new sales staff influences the future availability and marketing of dry eye treatments.